<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898923</url>
  </required_header>
  <id_info>
    <org_study_id>ON101CLCT02</org_study_id>
    <nct_id>NCT01898923</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of WH-1 Ointment for the Treatment of Chronic Diabetic Foot Ulcers</brief_title>
  <acronym>WH-1</acronym>
  <official_title>Randomized Controlled Study to Evaluate the Efficacy and Safety of WH-1 Ointment for the Treatment of Chronic Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oneness Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oneness Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of the new treatment of WH-1
      ointment compared to Aquacel® Hydrofiber® dressing, applied to chronic diabetic foot ulcers
      for up to 16 weeks.An additional objective of this study is to collect safety information
      including adverse events and clinical laboratory abnormalities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is designed as a randomized, evaluator blinded, active-controlled, multi-center
      study comparing the efficacy and safety of WH-1 ointment and Aquacel® Hydrofiber® dressing in
      the treatment of diabetic foot ulcers. Independent evaluators who blinded to subjects'
      treatment will evaluate whether the wound has healed. Eligible subjects will be randomized to
      receive either WH-1 ointment or Aquacel® Hydrofiber® dressing in a 1:1 allocation. The study
      treatment will be applied to the selected ulcer for a maximum period of 16 weeks, until the
      wound/ulcer closure (wound size of 0) for two consecutive visits at least 2 weeks apart, or
      until the subject exited the study as treatment failure. After that, all subjects regardless
      of wound healing at the end of comparison period will be followed for 12 weeks to investigate
      durability. During the follow-up period, Aquacel® Hydrofiber® dressing will be applied for
      subjects who have unhealed or with recurrent wound. Each target ulcer with wound photographs
      for blind assessment will be monitored at each scheduled visit.

      One interim analysis is planned at around 50% of study information; the final analysis will
      be conducted at the end of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of complete ulcer closure</measure>
    <time_frame>16 weeks</time_frame>
    <description>The primary variable is the number of target ulcers healed in each group within 16 weeks. The primary efficacy outcome is the comparison of the incidence of complete healing of the target ulcer between the two treatment groups at the end of treatment.
For the purpose of this study a complete healing will be defined as complete epithelialization which is maintained with no drainage for at least 2 weeks and is confirmed by a blinded assessor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time of healing rate</measure>
    <time_frame>16 weeks</time_frame>
    <description>Time to complete ulcer healing, The time of the original healing will be taken as the time to healing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in ulcer area</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percentage change in ulcer surface area from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>50% reduction in ulcer area</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percentage of subjects with a 50% reduction of ulcer surface area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection of the target ulcer</measure>
    <time_frame>16 weeks</time_frame>
    <description>Incidence of infection of the target ulcer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Diabetic Foot</condition>
  <arm_group>
    <arm_group_label>WH-1 ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WH-1 ointment(1.25%),15g ointment per tube. Twice daily for up to 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aquacel® Hydrofiber® dressing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Aquacel® Hydrofiber® dressings will be changed daily, on alternate days or three times a week according to need, but not longer than 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WH-1 ointment</intervention_name>
    <arm_group_label>WH-1 ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aquacel® Hydrofiber® dressing</intervention_name>
    <arm_group_label>Aquacel® Hydrofiber® dressing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Has signed a written informed consent prior to the first study evaluation;

          2. Male or female is at least 20 and &lt; 80 years of age;

          3. Diabetes mellitus (type 1 or 2) with an HbA1c &lt; 12.0% measured during screening or
             within three months prior to randomization;

          4. An ankle brachial index on the target limb at least 0.8 measured during screening or
             within three months prior to randomization;

          5. The target ulcer must have the following characteristics:

               -  Grade 1 or 2 per Wagner Ulcer Classification System;

               -  No higher than the ankle;

               -  No active infected;

               -  A cross-sectional area of between 1 and 25 cm2 post-debridement;

               -  Present for at least 4 weeks before randomization;

          6. If female and of childbearing potential has a negative pregnancy test and is not
             breastfeeding at screening visit;

          7. Able and willing to attend the scheduled visits and comply with study procedures.

        Exclusion Criteria:

          1. Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement;

          2. Acute Charcot's neuroarthropathy as determined by clinical and/or radiographic
             examination;

          3. Has undergone revascularization procedure aimed at increasing blood flow in the
             treatment target limb &lt; 4 weeks prior to randomization;

          4. Poor nutritional status defined as an albumin &lt; 2.5 g/dL;

          5. Aspartate Aminotransferase(AST, GOT) and/or Alanine Aminotransferase(ALT, GPT) &gt;3 x
             the normal upper limit;

          6. Serum Creatinine &gt;2 x the normal upper limit;

          7. Treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic
             corticosteroids less than 4 weeks before randomization;

          8. Use of any investigational drug or therapy within the 4 weeks prior to randomization;

          9. A psychiatric condition (e.g., suicidal ideation), current or chronic alcohol or drug
             abuse problem, determined from the subject's medical history, which, in the opinion of
             the Investigator, may pose a threat to subject compliance;

         10. Judged by the investigator not to be suitable for the study for any other reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Yao Huang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley Hung</last_name>
    <phone>+886-2-2570-2088</phone>
    <phone_ext>390</phone_ext>
    <email>ashley.hung@onenessbio.com.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei-Wen Tsung</last_name>
    <phone>+886-2-2570-2088</phone>
    <phone_ext>594</phone_ext>
    <email>weiwen.tsung@onenessbio.com.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Research Division</name>
      <address>
        <city>Taipei</city>
        <zip>115</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Ho</last_name>
      <phone>+886-2-2570-2088</phone>
      <phone_ext>312</phone_ext>
      <email>jessica.ho@onenessbio.com.tw</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Hung</last_name>
      <phone>+886-2-2570-2088</phone>
      <phone_ext>390</phone_ext>
      <email>ashley.hung@onenessbio.com.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Nai-Chen Cheng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kwang-Yi Tung, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shyi-Gen Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsuan-Li Huang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Yao Huang, PhD., M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsin-Han Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yung-Chang Hsu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tzong-Shiun Li, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ching-Chu Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rong-Hsing Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tzu-Yuan Wang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheng-Jyh Lin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chia-Meng Yu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shun-Cheng Chang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tim-Mo Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Niann-Tzyy Dai, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuan-Sheng Tzeng, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Hsin Wang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsin-Hua Chou, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuo-Suei Hung, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chung-Huei Huang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheng-Wei Lin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Ching Wang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ray-Houng Sun, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Yiu Tsai, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiun-Ting Yeh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hui-Mei Yang, Nurse Practitioner</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Chia Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kuo-Feng Huang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chin-Choon Yeh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chien-Chang Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pao-Yuan Lin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cherng-Kang Perng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tien-Shiang Wang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Chung Shih, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Hsun Lin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hao-Chih Tai, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chung-Chiao Lin, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-De Lu, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>I-Wen Chen, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shih-Yuan Hung, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kian-Yong Than, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jung-Fu Chen, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wen-Chieh Liao, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Szu-Hsien Wu, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2013</study_first_submitted>
  <study_first_submitted_qc>July 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2013</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>WH-1,Diabetic Foot,Ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

